trending Market Intelligence /marketintelligence/en/news-insights/trending/r3g61ac3mexm4pxa8zrswg2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Vifor partnering with ChemoCentryx on another kidney drug

State Of Singapore Online Video Subscription

Power Forecast Briefing: Capacity Shortfalls to Test the Renewable Energy Transition

Episode 43 - More Change, M&A On Horizon For Equity Research Industry

Cable Nets Struggle With Little Revenue Growth Expanding Programming Budgets


Vifor partnering with ChemoCentryx on another kidney drug

ChemoCentryx Inc. is expanding its alliance with Vifor Pharma to develop and commercialize another of its kidney drugs.

The companies will jointly develop CCX140 for more prevalent forms of chronic kidney disease with ChemoCentryx retaining rights in U.S. and China, and Vifor Pharma for the rest of the world.

ChemoCentryx will receive $50 million in upfront payment in exchange for the rights. It will also receive undisclosed payments once certain milestones are met, as well as royalty on future sales.

CCX140 previously cleared phase 2 clinical trial in patients with diabetic kidney disease.

Vifor Pharma first partnered with ChemoCentryx in May for rights to a possible treatment for rare and orphan kidney diseases, CCX168, in certain parts of the world.